Rare presentation of post-transplant lymphoproliferative disorder isolated to gastroesophageal junction.
World J Gastrointest Oncol.
2013 Dec 15;5(12):230-4. doi: 10.4251/wjgo.v5.i12.230. PubMed PMID:
24363831; PubMed Central PMCID:
PMC3868718.
An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.
Bone Marrow Transplant.
2014 Aug;49(8):1052-5. doi: 10.1038/bmt.2014.90. Epub 2014 May 5. PubMed PMID:
24797182; PubMed Central PMCID:
PMC4125480.
Investigational cancer drugs targeting cell metabolism in clinical development.
Expert Opin Investig Drugs.
2015 Jan;24(1):79-94. doi: 10.1517/13543784.2015.960077. Epub 2014 Sep 16. PubMed PMID:
25224845; PubMed Central PMCID:
PMC4434605.
The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma.
Front Oncol.
2015;5:136. doi: 10.3389/fonc.2015.00136. eCollection 2015. Review. PubMed PMID:
26137450; PubMed Central PMCID:
PMC4470273.
Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.
Am J Dermatopathol.
2015 Aug;37(8):604-13. doi: 10.1097/DAD.0000000000000266. PubMed PMID:
25839892; PubMed Central PMCID:
PMC4510028.
Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University.
Oncologist.
2015 Oct;20(10):1161-6. doi: 10.1634/theoncologist.2015-0175. Epub 2015 Aug 25. PubMed PMID:
26306900; PubMed Central PMCID:
PMC4591945.
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.
Curr Hematol Malig Rep.
2015 Dec;10(4):456-67. doi: 10.1007/s11899-015-0292-z. Review. PubMed PMID:
26449716; PubMed Central PMCID:
PMC4679542.
Tocilizumab for steroid refractory acute graft-versus-host disease.
Leuk Lymphoma.
2016;57(1):81-5. doi: 10.3109/10428194.2015.1045896. Epub 2015 Jul 3. PubMed PMID:
26140610; PubMed Central PMCID:
PMC4698359.
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy.
Leuk Lymphoma.
2016 May;57(5):1194-6. doi: 10.3109/10428194.2015.1055484. Epub 2016 Jan 6. PubMed PMID:
26734914.
Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk.
2016 Aug;16 Suppl(Suppl):S181-S190.e4. doi: 10.1016/j.clml.2016.02.014. PubMed PMID:
27521316; PubMed Central PMCID:
PMC4999299.
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Curr Hematol Malig Rep.
2016 Dec;11(6):514-527. doi: 10.1007/s11899-016-0355-9. Review. PubMed PMID:
27778143; PubMed Central PMCID:
PMC5199232.
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?.
Expert Rev Hematol.
2017 Feb;10(2):111-121. doi: 10.1080/17474086.2017.1270201. Epub 2016 Dec 26. Review. PubMed PMID:
27998183.
Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).
Discov Med.
2017 Mar;23(126):189-199. Review. PubMed PMID:
28472613; PubMed Central PMCID:
PMC5585079.
A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.
Bone Marrow Transplant.
2017 Apr;52(4):561-566. doi: 10.1038/bmt.2016.304. Epub 2017 Jan 9. PubMed PMID:
28067870; PubMed Central PMCID:
PMC5382040.
Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.
Int J Cancer.
2017 Apr 15;140(8):1899-1906. doi: 10.1002/ijc.30566. PubMed PMID:
27943278; PubMed Central PMCID:
PMC5323329.
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
N Engl J Med.
2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767. PubMed PMID:
28679093; PubMed Central PMCID:
PMC5628739.
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Blood.
2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3. PubMed PMID:
28468799; PubMed Central PMCID:
PMC5510790.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
J Natl Compr Canc Netw.
2018 Feb;16(2):123-135. doi: 10.6004/jnccn.2018.0007. PubMed PMID:
29439173.
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.
Blood Adv.
2018 Apr 24;2(8):933-940. doi: 10.1182/bloodadvances.2018018531. PubMed PMID:
29685953; PubMed Central PMCID:
PMC5916010.
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
Blood.
2018 Jul 5;132(1):9-16. doi: 10.1182/blood-2018-02-811174. Epub 2018 May 2. Review. PubMed PMID:
29720488.
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.
Clin Cancer Res.
2018 Jul 15;24(14):3273-3281. doi: 10.1158/1078-0432.CCR-17-2685. Epub 2018 Apr 9. PubMed PMID:
29632007; PubMed Central PMCID:
PMC6050103.
Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Biol Blood Marrow Transplant.
2018 Aug;24(8):1671-1677. doi: 10.1016/j.bbmt.2018.04.019. Epub 2018 Apr 21. PubMed PMID:
29684565.
Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
J Virol.
2018 Nov 1;92(21). doi: 10.1128/JVI.00813-18. Print 2018 Nov 1. PubMed PMID:
30089703; PubMed Central PMCID:
PMC6189503.
Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).
Cancer Treat Res.
2019;176:83-98. doi: 10.1007/978-3-319-99716-2_4. Review. PubMed PMID:
30596214.
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
J Hematol Oncol.
2019 Jan 10;12(1):6. doi: 10.1186/s13045-018-0696-z. PubMed PMID:
30630534; PubMed Central PMCID:
PMC6329157.
Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders.
Front Oncol.
2019;9:127. doi: 10.3389/fonc.2019.00127. eCollection 2019. Review. PubMed PMID:
30931253; PubMed Central PMCID:
PMC6428703.
Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL).
Front Oncol.
2019;9:509. doi: 10.3389/fonc.2019.00509. eCollection 2019. PubMed PMID:
31263679; PubMed Central PMCID:
PMC6584846.
Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation.
Bone Marrow Transplant.
2020 Apr;55(4):780-786. doi: 10.1038/s41409-019-0730-y. Epub 2019 Oct 29. PubMed PMID:
31664185.
Improved outcomes for extranodal natural killer T-cell lymphoma.
Lancet Haematol.
2020 Apr;7(4):e272-e273. doi: 10.1016/S2352-3026(20)30041-7. Epub 2020 Feb 24. PubMed PMID:
32105607.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
J Natl Compr Canc Netw.
2020 May;18(5):522-536. doi: 10.6004/jnccn.2020.0022. PubMed PMID:
32380458.
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Cancer.
2020 May 15;126(10):2279-2287. doi: 10.1002/cncr.32752. Epub 2020 Feb 12. PubMed PMID:
32049359; PubMed Central PMCID:
PMC7190439.
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.
Blood Adv.
2020 May 26;4(10):2227-2235. doi: 10.1182/bloodadvances.2020001554. PubMed PMID:
32442301; PubMed Central PMCID:
PMC7252552.
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
JAMA Oncol.
2020 Jul 1;6(7):1011-1018. doi: 10.1001/jamaoncol.2020.1278. PubMed PMID:
32496525; PubMed Central PMCID:
PMC7273311.
Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas: a single-institution experience.
Br J Dermatol.
2020 Aug;183(2):386-387. doi: 10.1111/bjd.18961. Epub 2020 Mar 25. PubMed PMID:
32078154.
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Cancers (Basel).
2020 Aug 15;12(8). doi: 10.3390/cancers12082293. PubMed PMID:
32824175; PubMed Central PMCID:
PMC7463651.
Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.
Blood Adv.
2020 Sep 8;4(17):4256-4266. doi: 10.1182/bloodadvances.2020001966. Review. PubMed PMID:
32898250; PubMed Central PMCID:
PMC7479955.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.
J Natl Compr Canc Netw.
2020 Nov 2;18(11):1460-1467. doi: 10.6004/jnccn.2020.0053. PubMed PMID:
33152703.
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Blood.
2021 Jan 21;137(3):374-386. doi: 10.1182/blood.2020006926. PubMed PMID:
32663292; PubMed Central PMCID:
PMC8765121.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Haematologica.
2021 Jul 1;106(7):1932-1942. doi: 10.3324/haematol.2020.270876. PubMed PMID:
33538152; PubMed Central PMCID:
PMC8252937.
A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort Study.
Front Med (Lausanne).
2021;8:679294. doi: 10.3389/fmed.2021.679294. eCollection 2021. PubMed PMID:
34277658; PubMed Central PMCID:
PMC8283488.
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Blood Adv.
2021 Jul 27;5(14):2852-2862. doi: 10.1182/bloodadvances.2021004458. PubMed PMID:
34283175; PubMed Central PMCID:
PMC8341354.
SMILE and Beam On.
Int J Radiat Oncol Biol Phys.
2021 Dec 1;111(5):1105. doi: 10.1016/j.ijrobp.2021.09.045. PubMed PMID:
34793729.
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw.
2022 Mar;20(3):285-308. doi: 10.6004/jnccn.2022.0015. PubMed PMID:
35276674.
Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy.
Clin Lymphoma Myeloma Leuk.
2023 Jan;23(1):49-56. doi: 10.1016/j.clml.2022.09.009. Epub 2022 Oct 7. PubMed PMID:
36335021.
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
Leuk Lymphoma.
2023 Jan;64(1):107-118. doi: 10.1080/10428194.2022.2140281. Epub 2022 Nov 2. PubMed PMID:
36323309.
Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma.
Cancers (Basel).
2023 Feb 21;15(5). doi: 10.3390/cancers15051366. Review. PubMed PMID:
36900160; PubMed Central PMCID:
PMC10000128.
CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
FEBS Open Bio.
2023 Jul;13(7):1309-1319. doi: 10.1002/2211-5463.13625. Epub 2023 May 15. PubMed PMID:
37157185; PubMed Central PMCID:
PMC10315799.
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Br J Haematol.
2023 Aug;202(3):525-529. doi: 10.1111/bjh.18885. Epub 2023 May 22. PubMed PMID:
37217196; PubMed Central PMCID:
PMC11220724.
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Blood Adv.
2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. PubMed PMID:
37026796; PubMed Central PMCID:
PMC10425681.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Blood Adv.
2023 Oct 24;7(20):6339-6350. doi: 10.1182/bloodadvances.2023010330. PubMed PMID:
37530631; PubMed Central PMCID:
PMC10587711.
What would you like to do?